市場調查報告書
商品編碼
1542526
全球 AAV 合約開發和製造組織市場研究報告 - 2024 年至 2032 年行業分析、規模、佔有率、成長、趨勢和預測Global AAV Contract Development And Manufacturing Organizations Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032 |
全球 AAV 合約開發和製造組織市場需求預計將從 2023 年的 6.8398 億美元達到近 29.9921 億美元的市場規模,2024 年至 2032 年研究期間的複合年成長率為 17.85%。
AAV(腺相關病毒)合約開發和製造組織 (CDMO) 是專門從事基於 AAV 的基因療法的開發、製造和測試的公司。 AAV 是一種小型非致病性病毒,通常用作基因治療中基因傳遞的載體。 AAV CDMO 與客戶合作,針對特定治療應用設計和最佳化 AAV 載體。他們還提供 AAV 載體的生產服務,包括細胞系的開發、載體生產過程的最佳化以及最終產品的純化和表徵。此外,AAV CDMO 對 AAV 載體進行嚴格的測試,以確保安全性和有效性,包括效力、純度、無菌和身份測試。
隨著越來越多的基因治療產品被批准用於臨床,基因治療市場正在迅速擴大。 AAV 載體是基因治療遞送的熱門選擇,對基因治療的需求不斷成長正在推動 AAV CDMO 市場的成長。 AAV 載體技術的進步改進了載體生產流程、提高了轉導效率並減少了免疫反應。這些進步使 AAV 載體對基因療法應用更具吸引力,並增加了對 AAV CDMO 服務的需求。近年來,基因治療研究的資金供應大幅增加,政府機構、私人投資者和非營利組織都為基因治療市場的成長做出了貢獻。這筆資金正在推動新基因療法的開發,進而增加對 AAV CDMO 服務的需求。 FDA 等監管機構已表示支持基因療法的開發,並實施了基因療法產品的快速批准途徑。這種監管支持有助於推動基因治療市場的成長,包括 AAV CDMO 市場。許多生技和製藥公司選擇將基因治療製造外包給專門的 CDMO,而不是投資昂貴的內部設施。這一趨勢導致對 AAV CDMO 服務的需求不斷增加,因為這些公司正在尋找經驗豐富的合作夥伴來幫助他們開發和製造基因療法產品。
研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外,這些工具還對 AAV 合約開發和製造組織全球市場的每個細分市場進行包容性評估。 AAV 合約開發和製造組織行業的成長和趨勢為本研究提供了整體方法。
AAV 合約開發和製造組織市場報告的這一部分提供了國家和地區層面細分市場的詳細資料,從而幫助策略家確定相應產品或服務的目標人群以及即將到來的機會。
本節涵蓋區域前景,重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲的 AAV 合約開發和製造組織市場當前和未來的需求。此外,該報告重點關注所有主要地區各個應用領域的需求、估計和預測。
該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。 AAV 合約開發和製造組織市場的主要參與者包括 Thermo Fischer Scientific Inc.、Creative Biogene、Catalent Inc.、Charles River Laboratories International Inc.、Danaher (Aldevron)、Forge Biologics、Genezen、ViroCell Biologics、Merck KGaA、Viralgen 、 Biovian Oy、Esco Lifesciences (Esco Aster Pte. Ltd.)、GenScript ProBio、Porton Advanced Solution Ltd、Ask Bio、Showa Denko、Takara Bio Inc. 本部分包含競爭格局的整體視圖,其中包括各種策略發展,例如作為關鍵的併購、未來產能、合作夥伴關係、財務概覽、合作、新產品開發、新產品發布和其他發展。
如果您有任何客製化要求,請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。
The global demand for AAV Contract Development And Manufacturing Organizations Market is presumed to reach the market size of nearly USD 2999.21 Million by 2032 from USD 683.98 Million in 2023 with a CAGR of 17.85% under the study period 2024 - 2032.
AAV (adeno-associated virus) Contract Development and Manufacturing Organizations (CDMOs) are companies that specialize in the development, manufacturing, and testing of AAV-based gene therapies. AAV is a small, non-pathogenic virus that is commonly used as a vector for gene delivery in gene therapy. AAV CDMOs work with clients to design and optimize AAV vectors for specific therapeutic applications. They also provide services for the production of AAV vectors, including the development of cell lines, optimization of vector production processes, and purification and characterization of the final product. In addition, AAV CDMOs conduct rigorous testing of the AAV vectors to ensure safety and efficacy, including tests for potency, purity, sterility, and identity.
The market for gene therapies is expanding rapidly as more gene therapy products are approved for clinical use. AAV vectors are a popular choice for gene therapy delivery, and the increasing demand for gene therapies is driving growth in the AAV CDMO market. Advances in AAV vector technology have led to improved vector production processes, increased transduction efficiency, and reduced immune responses. These advances have made AAV vectors more attractive for gene therapy applications and have increased the demand for AAV CDMO services. The availability of funding for gene therapy research has increased significantly in recent years, with government agencies, private investors, and non-profit organizations all contributing to the gene therapy market growth. This funding is driving the development of new gene therapies, which in turn is increasing demand for AAV CDMO services. Regulatory agencies such as the FDA have shown support for the development of gene therapies and have implemented expedited approval pathways for gene therapy products. This regulatory support is helping to drive growth in the gene therapy market, including the AAV CDMO market. Many biotech and pharma companies are choosing to outsource their gene therapy manufacturing to specialized CDMOs rather than investing in expensive in-house facilities. This trend is increasing demand for AAV CDMO services as these companies seek out experienced partners to help them develop and manufacture their gene therapy products.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of AAV Contract Development And Manufacturing Organizations. The growth and trends of AAV Contract Development And Manufacturing Organizations industry provide a holistic approach to this study.
This section of the AAV Contract Development And Manufacturing Organizations market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
This section covers the regional outlook, which accentuates current and future demand for the AAV Contract Development And Manufacturing Organizations market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the AAV Contract Development And Manufacturing Organizations market include Thermo Fischer Scientific Inc., Creative Biogene, Catalent Inc., Charles River Laboratories International Inc., Danaher (Aldevron), Forge Biologics, Genezen, ViroCell Biologics, Merck KGaA, Viralgen, Biovian Oy, Esco Lifesciences (Esco Aster Pte. Ltd.), GenScript ProBio, Porton Advanced Solution Ltd, Ask Bio, Showa Denko, Takara Bio Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.